0001104659-19-033994.txt : 20190605 0001104659-19-033994.hdr.sgml : 20190605 20190605144122 ACCESSION NUMBER: 0001104659-19-033994 CONFORMED SUBMISSION TYPE: N-CSRS PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190605 DATE AS OF CHANGE: 20190605 EFFECTIVENESS DATE: 20190605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TEKLA HEALTHCARE INVESTORS CENTRAL INDEX KEY: 0000805267 IRS NUMBER: 046564285 STATE OF INCORPORATION: MA FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: N-CSRS SEC ACT: 1940 Act SEC FILE NUMBER: 811-04889 FILM NUMBER: 19879486 BUSINESS ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 6177728515 MAIL ADDRESS: STREET 1: 100 FEDERAL STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: H&Q HEALTHCARE INVESTORS DATE OF NAME CHANGE: 19920703 N-CSRS 1 a19-7194_1ncsrs.htm N-CSRS

	OMB APPROVAL
	OMB Number:	3235-0570
	Expires:	August 31, 2020
UNITED STATES	Estimated average burden hours per response. . . . . . . . . . . . . . .20.6
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM N-CSR

CERTIFIED SHAREHOLDER REPORT OF REGISTERED
MANAGEMENT INVESTMENT COMPANIES

Investment Company Act file number			811-04889

Tekla Healthcare Investors
(Exact name of registrant as specified in charter)

100 Federal Street, 19th Floor, Boston, MA					02110
(Address of principal executive offices)					(Zip code)


(Name and address of agent for service)

Registrant’s telephone number, including area code:				617-772-8500

Date of fiscal year end:	September 30

Date of reporting period:		October 1, 2018 to March 31, 2019

ITEM 1. REPORTS TO STOCKHOLDERS.

TEKLA HEALTHCARE INVESTORS

Semiannual Report

March 31, 2019

Beginning on January 1, 2021, as permitted by regulations adopted by the Securities and Exchange Commission, paper copies of the Fund's annual and semi-annual shareholder reports will no longer be sent by mail, unless you specifically request paper copies of the reports. Instead, the reports will be made available on the Fund's website, teklacap.com., and you will be notified by mail each time a report is posted and provided with a website link to access the report.

Beginning on January 1, 2019, you may elect to receive all future reports in paper free of charge. If you invest through a financial intermediary, you can contact your financial intermediary to request that you continue to receive paper copies of your shareholder reports. If you invest directly with the Fund, you can call Computershare at 1-800-426-5523 to inform the Fund that you wish to continue receiving paper copies of your shareholder reports. Your election to receive reports in paper will apply to all funds held in your account if you invest through your financial intermediary or all funds held with the fund complex if you invest directly with the Fund.

TEKLA HEALTHCARE INVESTORS

Distribution policy: The Fund has implemented a managed distribution policy (the Policy) that provides for quarterly distributions at a rate set by the Board of Trustees. Under the current Policy, the Fund intends to make quarterly distributions at a rate of 2% of the Fund's net assets to shareholders of record. The Policy would result in a return of capital to shareholders, if the amount of the distribution exceeds the Fund's net investment income and realized capital gains. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund's investment performance and should not be confused with "yield" or "income."

The amounts and sources of distributions reported in the Fund's notices pursuant to Section 19(a) of the Investment Company Act of 1940 are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that tells you how to report distributions for federal income tax purposes.

You should not draw any conclusions about the Fund's investment performance from the amount of distributions pursuant to the Policy or from the terms of the Policy. The Policy has been established by the Trustees and may be changed or terminated by them without shareholder approval. The Trustees regularly review the Policy and the frequency and rate of distributions considering the purpose and effect of the Policy, the financial market environment, and the Fund's income, capital gains and capital available to pay distributions. The suspension or termination of the Policy could have the effect of creating a trading discount or widening an existing trading discount. At this time there are no reasonably foreseeable circumstances that might cause the Trustees to terminate the Policy.

Consider these risks before investing: As with any investment company that invests in equity securities, the Fund is subject to market risk—the possibility that the prices of equity securities will decline over short or extended periods of time. As a result, the value of an investment in the Fund's shares will fluctuate with the market generally and market sectors in particular. You could lose money over short or long periods of time. Political and economic news can influence marketwide trends and can cause disruptions in the U.S. or world financial markets. Other factors may be ignored by the market as a whole but may cause movements in the price of one company's stock or the stock of companies in one or more industries. All of these factors may have a greater impact on initial public offerings and emerging company shares. Different types of equity securities tend to shift into and out of favor with investors, depending on market and economic conditions. The performance of funds that invest in equity securities of Healthcare Companies may at times be better or worse than the performance of funds that focus on other types of securities or that have a broader investment style.

TEKLA HEALTHCARE INVESTORS

Dear Shareholders,

The healthcare/biotechnology sector was quite volatile during the six month period ended March 31, 2019. As can be seen in the graph below, the illustrated indices declined very significantly in the fourth quarter of 2018, particularly during December 2018. This was among the most aggressive short-term declines we have seen in recent years. Conversely, in the first quarter of 2019, we observed one of the most prolific short-term advances the healthcare/biotechnology sector has seen in many years. The result, while demonstrating quite high volatility in the report period, in aggregate left the sector and the Fund down moderately for the reporting period.

6 Month Performance Ending March 31, 2019

The question this leaves us with is: What happened and what might we expect going forward? Our sector is usually most affected by the results from individual scientific news, clinical trial results and regulatory approval/rejection as well as merger and acquisition (M&A) activity. We have observed such occurrences in recent months. During the first quarter of 2019, we saw both encouraging and disappointing events. These include a significant positive, the proposed acquisition of Celgene Corporation by Bristol-Myers Squibb Company, which is the biggest proposed acquisition in our sector in some years. Other significant and encouraging events were also seen. Conversely, the pivotal clinical trial failure of Biogen Inc.'s Aducanumab was also reported in the first quarter of 2019. The clinical trial result was probably the most highly anticipated event expected within the next year. Its failure has damaged the so-called amyloid hypothesis, a heretofore putative strategy for treating Alzheimer's Disease. We have certainly seen other positive clinical and regulatory developments in recent months but the Aducanumab trial failure was extremely disappointing.

We will continue to see, evaluate and report on positive and negative events, but we think macro related sentiment will have no less impact than events on sector performance in the short to intermediate term. As you are undoubtedly aware, in 2018 healthcare comprises nearly 18% of

U.S. GDP making it among the biggest sectors in the U.S. economy. Costs to provide healthcare products and services are widely considered to be too high. Opinions regarding how these costs should be controlled and paid for have been hotly debated for many years but have reached a crescendo of late. As the 2020 U.S. presidential election approaches, it is pretty clear to us that healthcare is and will be a topic that receives great attention. As prospects grow or fade for individual candidates (including the incumbent), we expect sentiment for, as well as the value of, the healthcare sector to improve or decline in tandem. We think that these macro factors will be as important to the healthcare sector as fundamentals for the next twelve to eighteen months.

In the medium to long term, headlines aside, we do not think there will be dramatic change in how healthcare is paid for or delivered. In the end, it seems likely to us that we will continue to have a system that is highly market dependent. Drugs that are differentiated and patent protected will sell well and receive premium pricing while generic drugs (which already comprise ~90% of prescriptions written) will also sell well but will be competitively priced. The Fund will continue to predominantly invest in companies that invent, develop and commercialize differentiated drugs that address unmet medical needs. We think that upon commercialization, such drugs will receive pricing that rewards the companies and their investors for risks taken in development and allow appropriate profit for the innovator. We will also continue to invest in companies that make generic drugs efficiently. We anticipate the general trend will be to increase utilization and that the "winners" in the generic drug space will be those that make (and sell) such drugs cheaply and well. Given that the quantity of generic drugs sold will continue to increase, we think there remains an opportunity to profitably invest in efficient manufacturers of such drugs.

We note that in the last ten years, the annualized return of the NASDAQ Biotechnology Index^®* ("NBI") (+18.31%) and the S&P Composite 1500^® Healthcare Index* ("S15HLTH") (+16.92%) has exceeded that of the S&P 500^® Index* ("SPX") (+15.91%).

As always, we thank you for your consideration of the Tekla Funds. Please call our distribution partner Destra Capital or us if you have any questions.

Be well,

Daniel R. Omstead, PhD
President and Portfolio Manager

TEKLA HEALTHCARE INVESTORS

Fund Essentials

Objective of the Fund

The Fund's investment objective is to seek long-term capital appreciation by investing primarily in securities of healthcare companies. In addition, the Fund seeks to provide regular distribution of realized capital gains.

Description of the Fund

Tekla Healthcare Investors ("HQH") is a non-diversified closed-end healthcare fund traded on the New York Stock Exchange under the ticker HQH. HQH primarily invests in healthcare industries and will emphasize both large established companies and smaller, emerging companies with a maximum of 40% of the Fund's assets in restricted securities of both public and private companies.

Investment Philosophy

Tekla Capital Management LLC, the Investment Adviser to the Fund, believes that:

• Aging demographics and adoption of new medical products and services can provide long-term tailwinds for healthcare companies

• Late stage biotechnology product pipeline could lead to significant increases in biotechnology sales

• Robust M&A activity in healthcare may create additional investment opportunities

Fund Overview and Characteristics as of 3/31/19

Market Price¹				$20.54
NAV²				$22.69
Premium/(Discount)				-9.48%
Average 30 Day Volume				115,593
Net Assets				$960,576,598
Ticker				HQH
NAV Ticker				XHQHX
Commencement of Operations Date				4/22/87
Fiscal Year to Date Distributions per Share				$0.92

¹ The closing price at which the Fund's shares were traded on the exchange.

² Per-share dollar value of the Fund, calculated by dividing the total value of all the securities in its portfolio, plus any other assets and less liabilities, by the number of Fund shares outstanding.

Holdings of the Fund (Data is based on net assets)

Asset Allocation as of 3/31/19

Sector Diversification as of 3/31/19

This data is subject to change on a daily basis.

TEKLA HEALTHCARE INVESTORS

Largest Holdings by Issuer

(Excludes Short-Term Investments)

As of March 31, 2019
(Unaudited)

Issuer – Sector	% of Net Assets
Celgene Corporation – Biotechnology		7.8	%
Amgen Inc. – Biotechnology		7.0	%
Gilead Sciences, Inc. – Biotechnology		6.0	%
Vertex Pharmaceuticals Incorporated – Biotechnology		4.4	%
Biogen Inc. – Biotechnology		4.2	%
Illumina, Inc. – Life Sciences Tools & Services		4.1	%
Regeneron Pharmaceuticals, Inc. – Biotechnology		3.5	%
Alexion Pharmaceuticals, Inc. – Biotechnology		3.0	%
Incyte Corporation – Biotechnology		2.5	%
Merck & Co., Inc. – Pharmaceuticals		1.7	%
Johnson & Johnson – Pharmaceuticals		1.5	%
Seattle Genetics, Inc. – Biotechnology		1.5	%
Mylan N.V. – Pharmaceuticals		1.4	%
UnitedHealth Group Incorporated – Health Care Providers & Service		1.4	%
Pfizer Inc. – Pharmaceuticals		1.3	%
BioMarin Pharmaceutical Inc. – Biotechnology		1.3	%
Neurocrine Biosciences, Inc. – Biotechnology		1.2	%
Sarepta Therapeutics, Inc. – Biotechnology		1.2	%
bluebird bio, Inc. – Biotechnology		1.0	%
Zoetis Inc. – Pharmaceuticals		1.0	%

Fund Performance

HQH is a closed-end fund which invests predominantly in healthcare companies. Subject to regular consideration, the Trustees of HQH have instituted a policy of making quarterly distributions to shareholders. The Fund seeks to make such distributions in the form of long-term capital gains.

The Fund considers investments in companies of all sizes and in all healthcare subsectors, including but not limited to, biotechnology, pharmaceuticals, healthcare equipment, healthcare supplies, life science tools and services, healthcare distributors, managed healthcare, healthcare technology, and healthcare facilities. The Fund emphasizes innovation, investing both in public and pre-public venture companies. The Fund considers its venture investments to be a differentiating characteristic. Among the various healthcare subsectors, HQH has considered the biotechnology subsector, including both pre-public and public companies,

to be a key contributor to the healthcare sector. The Fund holds biotech assets, including both public and pre-public, often representing 50-65% of net assets.

There is no commonly published index which matches the investment strategy of HQH. The S15HLTH consists of more than 160 companies representing most or all of the healthcare subsectors in which HQH typically invests; biotechnology often represents 15-20% of this index. By contrast, the NBI, which contains approximately 220 constituents, is much more narrowly constructed. The vast majority of this index is comprised of biotechnology, pharmaceutical and life science tools companies. In recent years, biotechnology has often represented 72-82% of the NBI. Neither the S15HLTH nor NBI indices contain any material amount of pre-public company assets.

Given these circumstances, we present both NAV and stock returns for the Fund in comparison to several commonly published indices. One index, the SPX, is a commonly considered broad based index; this index is comprised of companies in many areas of the economy, including, but not limited to healthcare. As described above, the NBI is a healthcare index mostly focused in three healthcare sectors with a uniquely high level of biotechnology comparison. The S15HLTH contains a wider representation of healthcare subsectors, but typically contains a much lower biotechnology composition.

HQH generally invests in a combination of large cap growth-oriented and earlier stage innovative healthcare companies with a focus on the biotechnology sector. Generally, HQH targets biotechnology exposure below that of the NBI and a higher biotechnology exposure than that of the S15HLTH. We note that, in recent periods, biotechnology has been a significant contributor to returns (both positive and negative) associated with those indices. We believe this sector continues to have significant potential for growth in the future.

Fund Performance for the Period Ended March 31, 2019

Period	HQH NAV		HQH MKT		NBI		S15HLTH		SPX
6 month		-7.00		-6.83		-8.18		-3.37		-1.73
1 year		6.28		4.43		5.24		14.63		9.48
5 year		5.49		3.41		7.74		11.72		10.90
10 year		14.73		16.19		18.31		16.92		15.91

All performance over one-year has been annualized.

Performance data quoted represents past performance, which is no guarantee of future results, and current performance may be lower or higher than the figures shown. The NAV total return takes into account the Fund's total annual expenses and does not reflect transaction charges. If transaction charges were reflected, NAV total return would be reduced. All distributions are assumed to be reinvested either in accordance with the dividend reinvestment plan (DRIP) for market price returns or NAV for NAV returns. Until the dRIP price is available from the Plan Agent, the market price returns reflect the reinvestment at the closing market price on the last business day of the month. Once the DRIP is available around mid-month, the market price returns are updated to reflect reinvestment at the DRIP price.

Portfolio Highlights as of March 31, 2019

Among other investments, Tekla Healthcare Investors' performance benefitted in the past six months by the following:

AbbVie Inc (ABBV) is a large-cap biotech company whose portfolio includes the world's best-selling drug, HUMIRA ($18.4B in 2018 global sales). The arrival of HUMIRA biosimilars in Europe in October 2018 has caused the stock to decline, with stronger adoption and greater pricing pressure than initially expected. We remain underweight ABBV as we remain concerned about biosimilar competition in the US (expected launches in 2023) and a weak late-stage pipeline unlikely to offset lost sales.

Incyte Corporation (INCY) appreciated during the recent quarter after languishing for much of 2018 following two unfavorable events around their two lead assets in development, epicadostat and baricitinib. The company has a stable and growing commercial base around the hematologic drugs Jakafi and ICLUSIG; this franchise could attract a potential acquirer and the stock overshot on the downside in 2018. This recent appreciation helped the Fund's overweight position in the stock.

Celgene Corporation (CELG) is a leader in hematological malignancies; in particular multiple myeloma that has been expanding its footprint into both solid tumors and inflammation with mixed success. In January, Bristol-Myers Squibb bid to acquire Celgene with a mix of cash, stock and a CVR for three products in late stage development. We are positively inclined towards the merged entity and this acquisition was recently approved by Bristol-Myers Squibb shareholders.

Among other examples, HQH's performance was negatively impacted by the following investments:

Neurocrine Biosciences, Inc. (NBIX) is a mid-cap biotech company focused on brain and endocrine disease. Its two main drugs, Ingrezza for tardive dyskinesia and Orlissa for endometriosis (partnered with ABBV) have been selling well; however, the stock took a hit following the Phase 3 failure of Ingrezza for Tourette's.

Ionis Pharmaceuticals (IONS) is transforming into a multiple product commercial company. However, we have reservations about the wide applicability of the RNA-targeted modality of their products and have been hesitant to be overweight the stock. During 1Q19, the financial community focused much attention on its partnered late stage asset for Huntington's disease in phase II/III, a genetic disorder that has been challenging to treat. The stock's recent appreciation hurts the Fund's performance in the period under review.

Spark Therapeutics Inc. (ONCE) is a smid cap commercial gene therapy company that had a single marketed product, Luxturna, in a small indication for a rare genetic form of vision loss. It also had a pipeline of assets that, after several clinical setbacks, materially lagged its peers either in competitiveness of public data or phase of development. For this reason, we were underweight the stock heading into a key data update mid 2019. Despite these shortcomings, Roche Holding AG (ROG SW) announced it would acquire Spark Therapeutics on February 22, 2019 for a substantial premium.

*The trademarks NASDAQ Biotechnology Index^®, S&P Composite 1500^® Healthcare Index and S&P 500^® Index referenced in this report are the property of their respective owners. These trademarks are not owned by or associated with the Fund or its service providers, including Tekla Capital Management LLC.

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2019

(Unaudited)

SHARES		CONVERTIBLE PREFERRED AND WARRANTS ^(a) - 3.3% of Net Assets	VALUE
		Biotechnology - 2.3%
	326,667	Amphivena Therapeutics, Inc. Series B (Restricted) ^{(b) (c)}	$	4,900,001
	525,972	Amphivena Therapeutics, Inc. Series C, 6.00% (Restricted) ^{(b) (c)}		1,887,315
	708,154	Atreca, Inc. Series C1 (Restricted) ^(b)		1,649,999
	968,073	Decipher Biosciences, Inc. Series II, 8.00% (Restricted) ^(b)		878,042
	962,412	Decipher Biosciences, Inc. Series III, 8.00% (Restricted) ^(b)		2,090,360
	1,043,219	Galera Therapeutics, Inc. Series C, 6.00% (Restricted) ^(b)		2,310,000
	249,700	Oculis SA, Series B2 (Restricted) ^{(b) (d)}		2,087,876
	2,692,309	Rainier Therapeutics, Inc. Series A, 6.00% (Restricted) ^(b)		1,750,001
	1,559,715	Rainier Therapeutics, Inc. Series B, 6.00% (Restricted) ^(b)		1,166,667
	875,000	Therachon Holding AG Series B, 8.00% (Restricted) ^(b)		3,500,000
	210,000	Trillium Therapeutics, Inc. Series II ^(d)		138,599
				22,358,860
		Health Care Equipment & Supplies (Restricted) ^(b) - 0.2%
	114,158	CardioKinetix, Inc. Series C, 8.00%		0
	205,167	CardioKinetix, Inc. Series D, 8.00%		0
	632,211	CardioKinetix, Inc. Series E, 8.00%		0
	692,715	CardioKinetix, Inc. Series F, 8.00%		0
	N/A ^(e)	CardioKinetix, Inc. Warrants (expiration 12/11/19, exercise price $0.69)		0
	N/A ^(e)	CardioKinetix, Inc. Warrants (expiration 06/03/20, exercise price $0.69)		0
	12,695	CardioKinetix, Inc. Warrants (expiration 08/15/24, exercise price $2.85)		0
	951,000	IlluminOss Medical, Inc. Series AA, 8.00%		951,000
	895,848	IlluminOss Medical, Inc. Junior Preferred, 8.00%		895,848
	71,324	IlluminOss Medical, Inc. Warrants (expiration 03/31/27, exercise price $1.00)
	59,426	IlluminOss Medical, Inc. Warrants (expiration 09/06/27, exercise price $1.00)		0

The accompanying notes are an integral part of these financial statements.
8

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2019

(Unaudited, continued)

SHARES		Health Care Equipment & Supplies (Restricted) ^(b) - continued	VALUE
	23,771	IlluminOss Medical, Inc. Warrants (expiration 11/20/27, exercise price $1.00)	$	0
	47,542	IlluminOss Medical, Inc. Warrants (expiration 01/11/28, exercise price $1.00)		0
	47,542	IlluminOss Medical, Inc. Warrants (expiration 02/06/28, exercise price $1.00)		0
	46,462	IlluminOss Medical, Inc. Warrants (expiration 01/29/29, exercise price $1.00)		0
				1,846,848
		Pharmaceuticals (Restricted) ^(b) - 0.8%
	3,173,164	Curasen Therapeutics, Inc. Series A ^(c)		3,500,000
	1,538,235	Milestone Pharmaceuticals, Inc. Series C, 8.00% ^(d)		2,099,998
	1,076,939	Milestone Pharmaceuticals, Inc. Series D1, 8.00% ^(d)		1,909,090
				7,509,088
		TOTAL CONVERTIBLE PREFERRED AND WARRANTS (Cost $45,098,098)		31,714,796
PRINCIPAL AMOUNT		CONVERTIBLE NOTES (Restricted) ^(b) - 0.2% of Net Assets
		Biotechnology - 0.1%
$	442,570	Rainier Therapeutics, Inc. Promissory Note, 8.00%, due 01/30/20		442,570
	442,570	Rainier Therapeutics, Inc. Promissory Note, 8.00%, due 01/30/20		442,570
				885,140
		Health Care Equipment & Supplies ^(b) - 0.1%
	74,456	CardioKinetix, Inc. Promissory Note, 5.00%, due 04/30/19		0
	285,294	IlluminOss Medical, Inc. Promissory Note, 8.00%, due 06/30/19		285,294
	95,083	IlluminOss Medical, Inc. Promissory Note, 8.00%, due 06/30/19		95,083
	190,166	IlluminOss Medical, Inc. Promissory Note, 8.00%, due 06/30/19		190,166
	190,166	IlluminOss Medical, Inc. Promissory Note, 8.00%, due 06/30/19		190,166

The accompanying notes are an integral part of these financial statements.
9

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2019

(Unaudited, continued)

PRINCIPAL AMOUNT		Health Care Equipment & Supplies ^(b) - continued	VALUE
$	237,708	IlluminOss Medical, Inc. Promissory Note, 8.00%, due 06/30/19	$	237,708
	185,849	IlluminOss Medical, Inc. Promissory Note, 8.00%, due 06/30/19		185,850
				1,184,267
		TOTAL CONVERTIBLE NOTES (Cost $2,144,143)		2,069,407
SHARES		COMMON STOCKS AND WARRANTS - 89.7% of Net Assets
		Biotechnology - 61.7%
	11,814	AbbVie Inc.		952,090
	119,074	AC Immune SA ^{(a) (d)}		601,324
	72,510	ACADIA Pharmaceuticals, Inc. ^(a)		1,946,894
	147,674	Akebia Therapeutics, Inc. ^(a)		1,209,450
	86,667	Albireo Pharma, Inc. ^(a)		2,791,544
	213,736	Alexion Pharmaceuticals, Inc. ^(a)		28,892,832
	137,956	Alkermes plc ^(a)		5,034,014
	24,414	Allakos Inc. ^(a)		988,767
	88,605	Alnylam Pharmaceuticals, Inc. ^(a)		8,280,137
	364,971	Amarin Corporation plc ^{(a) (f)}		7,576,798
	351,880	Amgen Inc.		66,850,162
	202,068	Amicus Therapeutics, Inc. ^(a)		2,748,125
	45,862	AnaptysBio, Inc. ^(a)		3,350,219
	31,146	Arena Pharmaceuticals, Inc. ^(a)		1,396,275
	18,519	argenx SE ^{(a) (f)}		2,311,912
	261,150	Array Biopharma Inc. ^(a)		6,366,837
	38,069	Ascendis Pharma A/S ^{(a) (f)}		4,480,721
	31,680	Athenex, Inc. ^(a)		388,080
	26,960	Audentes Therapeutics, Inc. ^(a)		1,051,979
	54,497	BeiGene, Ltd. ^{(a) (f)}		7,193,604
	169,612	Biogen Inc. ^{(a) (h)}		40,092,885
	135,723	BioMarin Pharmaceutical Inc. ^(a)		12,056,274
	59,660	bluebird bio, Inc. ^(a)		9,386,308
	90,055	Blueprint Medicines Corporation ^(a)		7,208,903
	798,651	Celgene Corporation ^(a)		75,344,735
	52,600	Clovis Oncology, Inc. ^(a)		1,305,532
	243,482	Coherus BioSciences, Inc. ^(a)		3,321,094
	123,392	CRISPR Therapeutics AG ^{(a) (d)}		4,407,562
	48,794	Editas Medicine, Inc. ^(a)		1,193,013

The accompanying notes are an integral part of these financial statements.
10

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2019

(Unaudited, continued)

SHARES		Biotechnology - continued	VALUE
	188,533	Epizyme, Inc. ^(a)	$	2,335,924
	108,846	Esperion Therapeutics, Inc. ^(a)		4,370,167
	371,638	Exelixis, Inc. ^(a)		8,844,984
	110,278	FibroGen, Inc. ^(a)		5,993,609
	30,904	Galapagos NV ^{(a) (f)}		3,639,873
	892,360	Gilead Sciences, Inc.		58,012,324
	54,124	Global Blood Therapeutics, Inc. ^(a)		2,864,783
	280,578	Incyte Corporation ^(a)		24,132,514
	101,896	Intellia Therapeutics, Inc. ^(a)		1,740,384
	38,641	Intercept Pharmaceuticals, Inc. ^(a)		4,322,382
	65,274	Ionis Pharmaceuticals, Inc. ^(a)		5,298,291
	127,421	Iovance Biotherapeutics, Inc. ^(a)		1,211,774
	12,271	Ligand Pharmaceuticals, Inc. ^(a)		1,542,587
	223,698	Merus N.V. ^{(a) (d)}		3,304,019
	81,916	Molecular Templates, Inc. ^(a)		475,932
	14,228	Myriad Genetics, Inc. ^(a)		472,370
	147,820	Nektar Therapeutics ^(a)		4,966,752
	135,987	Neurocrine Biosciences, Inc. ^(a)		11,980,455
	347,884	Ovid Therapeutics Inc. ^(a)		615,755
	1,297,531	Pieris Pharmaceuticals, Inc. ^(a)		4,346,729
	54,790	Pieris Pharmaceuticals, Inc., Series A Warrants (expiration 06/08/21, exercise price $3.00) ^{(a) (b)}		53,146
	27,394	Pieris Pharmaceuticals, Inc., Series B Warrants (expiration 06/08/21, exercise price $2.00) ^{(a) (b)}		35,886
	70,557	Portola Pharmaceuticals, Inc. ^(a)		2,448,328
	116,714	Protagonist Therapeutics, Inc. ^(a)		1,467,095
	41,261	PTC Therapeutics, Inc. ^(a)		1,553,064
	35,515	Puma Biotechnology, Inc. ^(a)		1,377,627
	81,650	Regeneron Pharmaceuticals, Inc. ^(a)		33,527,123
	55,964	Sage Therapeutics, Inc. ^(a)		8,901,074
	176,239	Sangamo Therapeutics, Inc. ^(a)		1,681,320
	96,867	Sarepta Therapeutics, Inc. ^(a)		11,545,578
	192,587	Seattle Genetics, Inc. ^(a)		14,105,072
	447,797	Sutro Biopharma, Inc. ^(a)		5,100,408
	317,526	Trillium Therapeutics, Inc. ^{(a) (d)}		209,567
	53,419	Ultragenyx Pharmaceutical Inc. ^(a)		3,705,142
	34,119	United Therapeutics Corporation ^(a)		4,004,547
	229,110	Vertex Pharmaceuticals Incorporated ^(a)		42,144,785
	79,586	Viking Therapeutics, Inc. ^(a)		791,085
	36,743	Xencor, Inc. ^(a)		1,141,238
				592,991,763

The accompanying notes are an integral part of these financial statements.
11

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2019

(Unaudited, continued)

SHARES			VALUE
		Drug Discovery Technologies - 0.0%
	117,030	ImmunoGen, Inc. ^(a)	$	317,151
		Health Care Equipment & Supplies - 3.2%
	64,992	Abbott Laboratories		5,195,460
	6,128	ABIOMED, Inc. ^(a)		1,750,096
	103,950	Alliqua BioMedical, Inc. ^(a)		305,613
	21,833	Baxter International Inc.		1,775,241
	2,140	Becton, Dickinson and Company		534,422
	160,000	Cercacor Laboratories, Inc. (Restricted) ^{(a) (b)}		786,802
	25,327	DENTSPLY Sirona, Inc.		1,255,966
	19,960	IDEXX Laboratories, Inc. ^(a)		4,463,056
	70,363	Medtronic plc		6,408,662
	38,804	NovoCure Limited ^(a)		1,869,189
	29,890	Stryker Corporation		5,903,873
	10,735	TherOx, Inc. (Restricted) ^{(a) (b)}		215
	7,713	Zimmer Biomet Holdings, Inc.		984,950
				31,233,545
		Health Care Providers & Services - 3.1%
	69,045	Acadia Healthcare Company, Inc. ^(a)		2,023,709
	23,201	Anthem, Inc.		6,658,223
	19,832	Cigna Corporation ^(a)		3,189,382
	67,759	CVS Health Corporation		3,654,243
	222,222	InnovaCare Health, Inc. (Restricted) ^{(a) (b) (g)}		735,555
	54,672	UnitedHealth Group Incorporated		13,518,199
				29,779,311
		Health Care Technology - 0.1%
	42,150	Evolent Health, Inc. ^(a)		530,247
		Healthcare Services - 0.2%
	6,284	Laboratory Corporation of America Holdings ^(a)		961,326
	20,101	Syneos Health, Inc. ^(a)		1,040,428
				2,001,754
		Life Sciences Tools & Services - 5.8%
	13,464	Bio-Techne Corporation		2,673,277
	126,003	Illumina, Inc. ^(a)		39,147,872
	77,573	PRA Health Sciences, Inc. ^(a)		8,555,526
	21,105	Thermo Fisher Scientific Inc.		5,776,861
				56,153,536

The accompanying notes are an integral part of these financial statements.
12

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2019

(Unaudited, continued)

SHARES			VALUE
		Medical Devices and Diagnostics - 1.6%
	3,773	Align Technology, Inc. ^(a)	$	1,072,777
	72,988	Boston Scientific Corporation ^(a)		2,801,280
	32,315	Danaher Corporation		4,266,226
	18,428	Genomic Health, Inc. ^(a)		1,290,881
	6,022	Intuitive Surgical, Inc. ^(a)		3,436,033
	22,100	ResMed Inc.		2,297,737
				15,164,934
		Pharmaceuticals - 14.0%
	124,692	Acceleron Pharma Inc. ^(a)		5,806,906
	47,564	Aerie Pharmaceuticals, Inc. ^(a)		2,259,290
	511,461	Aerpio Pharmaceuticals, Inc. ^(a)		460,878
	57,152	Agios Pharmaceuticals, Inc. ^(a)		3,854,331
	16,518	Allergan plc		2,418,400
	172,920	ArQule, Inc. ^(a)		828,287
	124,219	Bristol-Myers Squibb Company		5,926,489
	31,507	Concert Pharmaceuticals, Inc. ^(a)		380,289
	49,480	Eli Lilly and Company		6,420,525
	465,507	Endo International plc ^(a)		3,738,021
	210,543	Foamix Pharmaceuticals Ltd. ^{(a) (d)}		789,536
	22,307	GW Pharmaceuticals plc ^{(a) (f)}		3,760,291
	195,898	Immunomedics, Inc. ^(a)		3,763,201
	76,880	Intra-Cellular Therapies, Inc. ^(a)		936,398
	44,382	Jazz Pharmaceuticals plc ^(a)		6,344,407
	103,689	Johnson & Johnson		14,494,685
	9,280	Madrigal Pharmaceuticals, Inc. ^(a)		1,162,413
	228,782	Marinus Pharmaceuticals, Inc. ^(a)		956,309
	132,804	Medicines Company (The) ^(a)		3,711,872
	198,642	Merck & Co., Inc.		16,521,055
	9,460	Mirati Therapeutics, Inc. ^(a)		693,418
	489,519	Mylan N.V. ^(a)		13,872,968
	26,860	MyoKardia, Inc. ^(a)		1,396,451
	302,493	Pfizer Inc.		12,846,878
	17,320	Rhythm Pharmaceuticals, Inc. ^(a)		474,741
	79,790	Spectrum Pharmaceuticals, Inc. ^(a)		852,955
	574,944	Tetraphase Pharmaceuticals, Inc. ^(a)		770,425
	331,264	Teva Pharmaceutical Industries Limited ^{(a) (d) (f)}		5,194,220
	24,586	WaVe Life Sciences Ltd. ^(a)		955,166
	92,782	Zoetis Inc.		9,340,364
	56,684	Zogenix, Inc. ^(a)		3,118,187
				134,049,356
		TOTAL COMMON STOCKS AND WARRANTS (Cost $635,181,786)		862,221,597

The accompanying notes are an integral part of these financial statements.
13

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2019

(Unaudited, continued)

SHARES		EXCHANGE TRADED FUND - 0.7% of Net Assets	VALUE
	73,849	SPDR S&P Biotech ETF	$	6,686,288
		TOTAL EXCHANGE TRADED FUND (Cost $5,196,053)		6,686,288
PRINCIPAL AMOUNT		SHORT-TERM INVESTMENT - 4.0% of Net Assets
$	38,139,000	Repurchase Agreement, Fixed Income Clearing Corp., repurchase Value $38,139,000, 0.50%, dated 03/29/19, due 04/01/19 (collateralized by U.S. Treasury Notes 2.75%, due 08/15/21, market value $38,904,591)		38,139,000
		TOTAL SHORT-TERM INVESTMENT (Cost $38,139,000)		38,139,000
		TOTAL INVESTMENTS BEFORE MILESTONE INTEREST - 97.9% (Cost $725,759,080)		940,831,088
INTERESTS		MILESTONE INTERESTS (Restricted) ^{(a) (b)} - 1.4% of Net Assets
		Health Care Equipment & Supplies - 0.5%
	1	Veniti Milestone Interest		4,593,349
				4,593,349
		Pharmaceuticals - 0.9%
	1	Afferent Milestone Interest		783,096
	1	Ethismos Research, Inc. Milestone Interest		0
	1	Neurovance Milestone Interest		2,683,575
	1	TargeGen Milestone Interest		5,360,662
				8,827,333
		TOTAL MILESTONE INTERESTS (Cost $9,439,483)		13,420,682

The accompanying notes are an integral part of these financial statements.
14

TEKLA HEALTHCARE INVESTORS

SCHEDULE OF INVESTMENTS

MARCH 31, 2019

(Unaudited, continued)

NUMBER OF CONTRACTS (100 SHARES EACH)/ NOTIONAL AMOUNT ($)	CALL OPTION CONTRACTS PURCHASED - 0.0%	VALUE
110/3,850,000	Biogen Inc. Jun20 350 Call	$	39,325
	CALL OPTION CONTRACTS PURCHASED (Premiums paid $568,637)		39,325
	TOTAL INVESTMENTS - 99.3% (Cost $735,767,200)		954,291,095
	OTHER ASSETS IN EXCESS OF LIABILITIES - 0.7%		6,285,503
	NET ASSETS - 100%	$	960,576,598

(a) Non-income producing security.

(b) Security fair valued using significant unobservable inputs. See Investment Valuation and Fair Value Measurements.

(d) Foreign security.

(e) Number of warrants to be determined at a future date.

(f) American Depository Receipt

(g) Security exempt from registration under Rule 144A of the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers.

(h) A portion of security is pledged as collateral for calll option purchased.

The accompanying notes are an integral part of these financial statements.
15

TEKLA HEALTHCARE INVESTORS

STATEMENT OF ASSETS AND LIABILITIES

MARCH 31, 2019

(Unaudited)

ASSETS:
Investments in unaffiliated issuers, at value (cost $716,035,992)	$	930,583,098
Investments in affiliated issuers, at value (cost $10,291,725)		10,287,315
Milestone interests, at value (cost $9,439,483)		13,420,682
Total investments		954,291,095
Cash		724
Dividends and interest receivable		293,245
Receivable for investments sold		11,402,485
Prepaid expenses		21,175
Other assets (see Note 1)		1,189,264
Total assets		967,197,988
LIABILITIES:
Payable for investments purchased		5,552,984
Accrued advisory fee		753,950
Accrued investor support service fees		38,326
Accrued shareholder reporting fees		91,080
Accrued trustee fees		41,009
Accrued other		144,041
Total liabilities		6,621,390
Commitments and Contingencies (see Notes 1)
NET ASSETS	$	960,576,598
SOURCES OF NET ASSETS:
Shares of beneficial interest, par value $.01 per share, unlimited number of shares authorized, amount paid in on 42,340,890 shares issued and outstanding	$	786,259,910
Total distributable earnings (loss)		174,316,688
Total net assets (equivalent to $22.69 per share based on 42,340,890 shares outstanding)	$	960,576,598

The accompanying notes are an integral part of these financial statements.
16

TEKLA HEALTHCARE INVESTORS

STATEMENT OF OPERATIONS

SIX MONTHS ENDED MARCH 31, 2019

(Unaudited)

INVESTMENT INCOME:
Dividend income (net of foreign tax of $0)	$	3,601,898
Interest and other income		108,332
Total investment income		3,710,230
EXPENSES:
Advisory fees		4,457,395
Investor support service fees		234,122
Administration fees		102,894
Shareholder reporting		88,467
Custodian fees		85,606
Legal fees		84,899
Auditing fees		51,409
Trustees' fees and expenses		71,608
Transfer agent fees		27,568
Other (see Note 2)		118,825
Total expenses		5,322,793
Net investment loss		(1,612,563	)
REALIZED AND UNREALIZED GAIN (LOSS):
Net realized gain (loss) on: Investments in unaffiliated issuers		(13,704,288	)
Closed or expired option contracts written		35,549
Foreign currency transactions		7,231
Net realized loss		(13,661,508	)
Change in unrealized appreciation (depreciation)
Investments in unaffiliated issuers		(69,560,156	)
Investments in affiliated issuers		1,487
Milestone interest		967,822
Option contracts purchased		(529,312	)
Change in unrealized appreciation (depreciation)		(69,120,159	)
Net realized and unrealized gain (loss)		(82,781,667	)
Net decrease in net assets resulting from operations	($	84,394,230	)

The accompanying notes are an integral part of these financial statements.
17

TEKLA HEALTHCARE INVESTORS

STATEMENTS OF CHANGES IN NET ASSETS

	Six months ended March 31, 2019 (Unaudited)			Year ended September 30, 2018
NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS:
Net investment loss	($	1,612,563	)	($	4,120,803	)
Net realized gain (loss)		(13,661,508	)		69,465,831
Change in net unrealized appreciation (depreciation)		(69,120,159	)		3,858,574
Net increase (decrease) in net assets resulting from operations		(84,394,230	)		69,203,602
DISTRIBUTIONS TO SHAREHOLDERS FROM (See Note 1):
Distributions (net investment income, realized gain (loss), other)		(38,546,571	) *		(79,998,934	)
Total distributions		(38,546,571	)		(79,998,934	)
CAPITAL SHARE TRANSACTIONS:
Reinvestment of distributions (935,514 and 1,696,374 shares, respectively)		17,372,296			37,609,525
Fund shares repurchased (810,746 and 128,976 shares, respectively) (see Note 1)		(15,597,823	)		(2,711,761	)
Total capital share transactions		1,774,473			34,897,764
Net increase (decrease) in net assets		(121,166,328	)		24,102,432
NET ASSETS:
Beginning of period		1,081,742,926			1,057,640,494
End of period	$	960,576,598		$	1,081,742,926

* A portion of the distribution may be deemed a tax return of capital at year end.

The accompanying notes are an integral part of these financial statements.
18

TEKLA HEALTHCARE INVESTORS

FINANCIAL HIGHLIGHTS

	Six months ended March 31, 2019			Years ended September 30,
	(Unaudited)			2018			2017			2016			2015			2014
OPERATING PERFORMANCE FOR A SHARE OUTSTANDING THROUGHOUT EACH YEAR
Net asset value per share, beginning of period	$	25.62		$	26.02		$	24.99		$	29.61		$	29.40		$	24.90
Net investment loss ⁽¹⁾		(0.04	)		(0.10	)		(0.13	)		(0.17	)		(0.22	)		(0.24	)
Net realized and unrealized gain (loss)		(2.02	)		1.63			3.12			(1.35	)		3.04			7.66
Total increase (decrease) from investment operations		(2.06	)		1.53			2.99			(1.52	)		2.82			7.42
Distributions to shareholders from:
Net realized capital gains		(0.92	)		(1.94	)		(1.96	)		(3.10	)		(2.61	)		(2.13	)
Total distributions		(0.92	)		(1.94	)		(1.96	)		(3.10	)		(2.61	)		(2.13	)
Increase resulting from shares repurchased ⁽¹⁾		0.05			0.01			—	⁽²⁾		—			—			—
Change due to rights offering		—			—			—			—			—			(0.79	)⁽³⁾
Short term gain due to trading error		—			—			—			—			0.00	⁽²⁾		—
Net asset value per share, end of period	$	22.69		$	25.62		$	26.02		$	24.99		$	29.61		$	29.40
Per share market value, end of period	$	20.54		$	23.15		$	25.23		$	23.81		$	27.60		$	28.40
Total investment return at market value		(6.83	%)*		0.05	%		14.95	%		(3.19	%)		4.94	%		28.08	%
Total investment return at net asset value		(7.00	%)*		7.37	%		12.95	%		(5.29	%)		8.76	%⁽⁴⁾		27.64	%
RATIOS
Expenses to average net assets		1.12	%**		1.08	%		1.10	%		1.10	%		1.03	%		1.15	%
Expenses to average net assets with waiver		—			—			—			—			1.00	%		1.13	%
Net investment loss to average net assets		(0.34	%)**		(0.41	%)		(0.53	%)		(0.62	%)		(0.65	%)		(0.87	%)
SUPPLEMENTAL DATA
Net assets at end of period (in millions)	$	961		$	1,082		$	1,058		$	975		$	1,104		$	1,053
Portfolio turnover rate		18.98	%*		45.75	%		29.21	%		29.44	%		37.43	%		28.96	%

* Not Annualized

** Annualized

(1) Computed using average shares outstanding.

(2) Amount represents less than $0.005 per share.

(3) These rights offering shares were issued at a subscription price of $25.037 which was less than the Fund's net asset value per share of $29.01 on June 27, 2014 thus creating a dilution effect on the net asset value per share.

(4) Total return includes payment by the Adviser. Excluding this payment, total return would have been 8.68% at net asset value.

The accompanying notes are an integral part of these financial statements.
19

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2019

(Unaudited)

(1) Organization and Significant Accounting Policies

Tekla Healthcare Investors (the Fund) is a Massachusetts business trust formed on October 31, 1986 and registered under the Investment Company Act of 1940 as a non-diversified closed-end management investment company. The Fund commenced operations on April 22, 1987. The Fund's investment objective is long-term capital appreciation through investment in U.S. and foreign companies in the healthcare industry. The Fund invests primarily in securities of public and private companies that are believed by the Fund's Investment Adviser, Tekla Capital Management LLC (the Adviser), to have significant potential for above-average growth. The Fund may invest up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of U.S. issuers that are traded primarily in foreign markets.

The preparation of these financial statements requires the use of certain estimates by management in determining the Fund's assets, liabilities, revenues and expenses. Actual results could differ from these estimates and such differences could be material. The following is a summary of significant accounting policies followed by the Fund, which are in conformity with accounting principles generally accepted in the United States of America (GAAP). The Fund is an investment company and follows accounting and reporting guidance in the Financial Accounting Standards Board Accounting Standards Codification 946. Events or transactions occurring after March 31, 2019, through the date that the financial statements were issued, have been evaluated in the preparation of these financial statements.

Investment Valuation

Shares of publicly traded companies listed on national securities exchanges or trading in the over-the-counter market are typically valued at the last sale price, as of the close of trading, generally 4 p.m., Eastern time. The Board of Trustees of the Fund (the Trustees) has established and approved fair valuation policies and procedures with respect to securities for which quoted prices may not be available or which do not reflect fair value. Convertible bonds, corporate and government bonds are valued using a third-party pricing service. Convertible bonds are valued using this pricing service only on days when there is no sale reported. Restricted securities of companies that are publicly traded are typically valued based on the closing market quote on the valuation date adjusted for the impact of the restriction as determined in good faith by the Adviser also using fair valuation policies and procedures approved by the Trustees described below. Non-exchange traded warrants of publicly traded companies are generally valued using the Black-Scholes model, which incorporates both observable and unobservable inputs. Short-term investments with a maturity of 60 days or less are generally valued at amortized cost, which approximates fair value.

Convertible preferred shares, warrants or convertible note interests in private companies, milestone interests, and other restricted securities, as well as shares of publicly traded companies for which market quotations are not readily available, such as stocks for which trading has been halted or for which there are no current day sales, or which do not reflect fair value, are typically valued in good faith, based upon the recommendations made by the Adviser pursuant to fair valuation policies and procedures approved by the Trustees.

The Adviser has a Valuation Sub-Committee comprised of senior management which reports to the Valuation Committee of the Board at least quarterly. Each fair value determination is based on a consideration of relevant factors, including both observable and unobservable

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2019

(continued)

inputs. Observable and unobservable inputs the Adviser considers may include (i) the existence of any contractual restrictions on the disposition of securities; (ii) information obtained from the company, which may include an analysis of the company's financial statements, the company's products or intended markets or the company's technologies; (iii) the price of the same or similar security negotiated at arm's length in an issuer's completed subsequent round of financing; (iv) the price and extent of public trading in similar securities of the issuer or of comparable companies; or (v) a probability and time value adjusted analysis of contractual terms. Where available and appropriate, multiple valuation methodologies are applied to confirm fair value. Significant unobservable inputs identified by the Adviser are often used in the fair value determination. A significant change in any of these inputs may result in a significant change in the fair value measurement. Due to the uncertainty inherent in the valuation process, such estimates of fair value may differ significantly from the values that would have been used had a ready market for the investments existed, and differences could be material. Additionally, changes in the market environment and other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different from the valuations used at the date of these financial statements.

Milestone Interests

The Fund holds financial instruments which reflect the current value of future milestone payments the Fund may receive as a result of contractual obligations from other parties. The value of such payments are adjusted to reflect the estimated risk based on the relative uncertainty of both the timing and the achievement of individual milestones. A risk to the Fund is that the milestones will not be achieved and no payment will be received by the Fund. The milestone interests were received as part of the proceeds from the sale of four private companies. Any payments received are treated as a reduction of the cost basis of the milestone interest with payments received in excess of the cost basis treated as a realized gain. The contractual obligations with respect to the Milestone Interests provide for payments at various stages of the development of Afferent, Ethismos, Neurovance, TargeGen and Veniti's principal product candidate as of the date of the sale.

The following is a summary of the impact of the milestone interests on the financial statements as of and for the six months ended March 31, 2019:

Statement of Assets and Liabilities, Milestone interests, at value	$	13,420,682
Statement of Assets and Liabilities, Total distributable earning	$	3,981,199
Statement of Operations, Change in unrealized appreciation (depreciation) on milestone interests	$	967,822

Options on Securities

An option contract is a contract in which the writer (seller) of the option grants the buyer of the option, upon payment of a premium, the right to purchase from (call option) or sell to (put option) the writer a designated instrument at a specified price within a specified period of time. Certain options, including options on indices, will require cash settlement by the Fund if the option is exercised. The Fund enters into option contracts in order to hedge against potential adverse price movements in the value of portfolio assets, as a temporary substitute for selling selected investments, to lock in the purchase price of a security or currency which it expects to purchase in the near future, as a temporary substitute for purchasing selected investments, or to enhance potential gain or to gain or hedge exposure to financial market risk.

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2019

(continued)

The Fund's obligation under an exchange traded written option or investment in an exchange traded purchased option is valued at the last sale price or in the absence of a sale, the mean between the closing bid and asked prices. Gain or loss is recognized when the option contract expires, is exercised or is closed.

If the Fund writes a covered call option, the Fund foregoes, in exchange for the premium, the opportunity to profit during the option period from an increase in the market value of the underlying security above the exercise price. If the Fund writes a put option it accepts the risk of a decline in the market value of the underlying security below the exercise price. Over-the-counter options have the risk of the potential inability of counterparties to meet the terms of their contracts. The Fund's maximum exposure to purchased options is limited to the premium initially paid. In addition, certain risks may arise upon entering into option contracts including the risk that an illiquid secondary market will limit the Fund's ability to close out an option contract prior to the expiration date and that a change in the value of the option contract may not correlate exactly with changes in the value of the securities or currencies hedged.

All options on securities and securities indices written by the Fund are required to be covered. When the Fund writes a call option, this means that during the life of the option the Fund may own or have the contractual right to acquire the securities subject to the option or may maintain with the Fund's custodian in a segregated account appropriate liquid securities in an amount at least equal to the market value of the securities underlying the option. When the Fund writes a put option, this means that the Fund will maintain with the Fund's custodian in a segregated account appropriate liquid securities in an amount at least equal to the exercise price of the option.

The average number of outstanding call options written and options purchased for the six months ended March 31, 2019 were 36 and 110 respectively.

Derivatives not accounted for as hedging instruments under ASC 815	Statement of Assets and Liabilities Location		Statement of Operations Location
Equity Contracts	Assets, options purchased at value	$39,325	Net realized gain on closed or expired option contracts purchased		$—
			Change in unrealized appreciation (depreciation) on option contracts purchased	($	529,312	)

Other Assets

Other assets in the Statement of Assets and Liabilities consists of amounts due to the Fund at various times in the future in connection with the sale of investments in six private companies.

Investment Transactions and Income

Investment transactions are recorded on a trade date basis. Gains and losses from sales of investments are recorded using the "identified cost" method. Interest income is recorded on the accrual basis, adjusted for amortization of premiums and accretion of discounts. Dividend income is recorded on the ex-dividend date, less any foreign taxes withheld. Upon notification

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2019

(continued)

from issuers, some of the dividend income received may be redesignated as a reduction of cost of the related investment if it represents a return of capital.

The aggregate cost of purchases and proceeds from sales of investment securities (other than short-term investments) for the six months ended March 31, 2019 totaled $179,888,282 and $247,878,196, respectively.

Repurchase Agreements

In managing short-term investments the Fund may from time to time enter into transactions in repurchase agreements. In a repurchase agreement, the Fund's custodian takes possession of the underlying collateral securities from the counterparty, the market value of which is at least equal to the principal, including accrued interest, of the repurchase transaction at all times. In the event of default or bankruptcy by the other party to the agreement, realization and/or retention of the collateral by the Fund may be delayed. The Fund may enter into repurchase transactions with any broker, dealer, registered clearing agency or bank. Repurchase agreement transactions are not counted for purposes of the limitations imposed on the Fund's investment in debt securities.

Distribution Policy

Pursuant to a Securities and Exchange Commission exemptive order, the Fund may make periodic distributions that include capital gains as frequently as 12 times in any one taxable year in respect of its common shares, and the Fund has implemented a managed distribution policy (the Policy) providing for quarterly distributions at a rate set by the Board of Trustees. Under the current Policy, the Fund intends to make quarterly distributions at a rate of 2% of the Fund's net assets to shareholders of record. The Fund intends to use net realized capital gains when making quarterly distributions, if available, but the Policy would result in a return of capital to shareholders if the amount of the distribution exceeds the Fund's net investment income and realized capital gains. If taxable income and net long-term realized gains exceed the amount required to be distributed under the Policy, the Fund will at a minimum make distributions necessary to comply with the requirements of the Internal Revenue Code. The Policy has been established by the Trustees and may be changed by them without shareholder approval. The Trustees regularly review the Policy and the frequency and rate of distribution considering the purpose and effect of the Policy, the financial market environment, and the Fund's income, capital gains and capital available to pay distributions.

The Fund's policy is to declare quarterly distributions in stock. The distributions are automatically paid in newly-issued full shares of the Fund unless otherwise instructed by the shareholder. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts of the Fund's transfer agent who will have whole and fractional shares added to their accounts. The Fund's transfer agent delivers an election card and instructions to each registered shareholder in connection with each distribution. The number of shares issued will be determined by dividing the dollar amount of the distribution by the lower of net asset value or market price on the pricing date. If a shareholder elects to receive a distribution in cash, rather than in shares, the shareholder's relative ownership in the Fund will be reduced. The shares reinvested will be valued at the lower of the net asset value or market price on the pricing date. Distributions in stock will not relieve shareholders of any federal, state or local income taxes that may be payable on such distributions. Additional

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2019

(continued)

distributions, if any, made to satisfy requirements of the Internal Revenue Code may be paid in stock, as described above, or in cash.

Share Repurchase Program

In March 2019, the Trustees approved the renewal of the repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares in the open market for a one year period ending July 14, 2020. Prior to this renewal, in March 2018, the Trustees approved the renewal of the share repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares for a one year period ending July 14, 2019. The share repurchase program is intended to enhance shareholder value and potentially reduce the discount between the market price of the Fund's shares and the Fund's net asset value.

During the six months ended March 31, 2019, the Fund repurchased 810,746 shares at a total cost of $15,597,823. The weighted average discount per share between the cost of repurchase and the net asset value applicable to such shares at the date of repurchase was 11.10%.

During the year ended September 30, 2018 the Fund repurchased 128,976 shares at a total cost of $2,711,761. The weighted average discount per share between the cost of repurchase and net asset value applicable to such shares at the date of repurchase was 8.12%.

Federal Taxes

It is the Fund's policy to comply with the requirements of the Internal Revenue Code applicable to regulated investment companies and to distribute to its shareholders substantially all of its taxable income and its net realized capital gains, if any. Therefore, no Federal income or excise tax provision is required.

As of March 31, 2019, the Fund had no uncertain tax positions that would require financial statement recognition or disclosure. The Fund's federal tax returns are subject to examination by the Internal Revenue Service for a period of three years.

Distributions

The Fund records all distributions to shareholders on the ex-dividend date. Such distributions are determined in conformity with income tax regulations, which may differ from GAAP. These differences include temporary and permanent differences from losses on wash sale transactions, installment sale adjustments and ordinary loss netting to reduce short term capital gains. Reclassifications are made to the Fund's capital accounts to reflect income and gains available for distribution under income tax regulations.

Commitments and Contingencies

Under the Fund's organizational documents, its officers and Trustees may be indemnified against certain liabilities and expenses arising out of the performance of their duties to the Fund. Additionally, in the normal course of business, the Fund enters into agreements with service providers that may contain indemnification clauses. The Fund's maximum exposure under these agreements is unknown as this would involve future claims that may be made against the Fund that have not yet occurred. However, based on experience, the Fund expects the risk of loss to be remote.

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2019

(continued)

Investor Support Services

The Fund has retained Destra Capital Investment LLC (Destra) to provide investor support services in connection with the ongoing operation of the Fund. The Fund pays Destra a fee in an annual amount equal to 0.05% of the average aggregate daily value of the Fund's Managed Assets pursuant to the investor support services agreement.

(2) Investment Advisory and Other Affiliated Fees

The Fund has entered into an Investment Advisory Agreement (the Advisory Agreement) with the Adviser. Pursuant to the terms of the Advisory Agreement, the Fund pays the Adviser a monthly fee at the rate when annualized of (i) 2.50% of the average net assets for the month of its venture capital and other restricted securities up to 25% of net assets and (ii) for all other net assets, 0.98% of the average net assets up to $250 million, 0.88% of the average net assets for the next $250 million, 0.80% of the average net assets for the next $500 million and 0.70% of the average net assets thereafter. The aggregate fee would not exceed a rate when annualized of 1.36%.

The Fund has entered into a Services Agreement (the Agreement) with the Adviser. Pursuant to the terms of the Agreement, the Fund reimburses the Adviser for certain services related to a portion of the payment of salary and provision of benefits to the Fund's Chief Compliance Officer. During the six months ended March 31, 2019, these payments amounted to $55,219 and are included in the Other category of expenses in the Statement of Operations, together with insurance and other expenses incurred to unaffiliated entities. Expenses incurred pursuant to the Agreement as well as certain expenses paid for by the Adviser are allocated to the Fund in an equitable fashion as approved by the Trustees of the Fund who are also officers of the Adviser.

The Fund pays compensation to Independent Trustees in the form of a retainer, attendance fees, and additional compensation to Board and Committee chairpersons. The Fund does not pay compensation directly to Trustees or officers of the Fund who are also officers of the Adviser.

(3) Other Transactions with Affiliates

An affiliate company is a company in which the Fund holds 5% or more of the voting securities. Transactions involving such companies during the six months ended March 31, 2019 were as follows:

Affiliated Companies	Begining Value as of September 30, 2018		Purchases at Cost		Proceeds from Sales			Net Realized Gain/(Loss) on sale of Affiliated Companies		Change in Unrealized Appreciation/ Depreciation		Ending Value as of March 31, 2019
Amphivena Therapeutics, Inc.	$	5,714,797	$	1,887,315	($	816,284	)	$	—	$	1,487	$	6,787,315
IlluminOss Medical, Inc.		2,845,265		185,850		—			—		—		3,031,115	*
Curasen Therapeutics, Inc.		3,500,000		—		—			—		—		3,500,000
	$	12,060,062	$	2,073,165	($	816,284	)	$	—	$	1,487	$	13,318,430

* Not an affiliate at March 31, 2019.

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2019

(continued)

Affiliated Companies	Shares/ Principal Amount as of March 31, 2019		Dividend/ Interest Income from Affiliated Companies		Capital Gain Distributions from Affiliated Companies
Amphivena Therapeutics, Inc.		852,639	$	8,725	$	—
IlluminOss Medical, Inc.		3,327,181		42,404		—
Curasen Therapeutics, Inc.		3,173,164		—		—
		7,352,984	$	51,129	$	—

(4) Fair Value Measurements

The Fund uses a three-tier hierarchy to prioritize the assumptions, referred to as inputs, used in valuation techniques to measure fair value. The three-tier hierarchy of inputs is summarized in the three broad levels. Level 1 includes quoted prices in active markets for identical investments. Level 2 includes prices determined using other significant observable inputs (including quoted prices for similar investments, interest rates, credit risk, etc.). The independent pricing vendor may value bank loans and debt securities at an evaluated bid price by employing methodologies that utilize actual market transactions, broker-supplied valuations, and/or other methodologies designed to identify the market value for such securities and such securities are considered Level 2 in the fair value hierarchy. Level 3 includes prices determined using significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments). These inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the levels used as of March 31, 2019 to value the Fund's net assets.

Assets at Value	Level 1		Level 2		Level 3		Total
Convertible Preferred And Warrants
Biotechnology	$	138,599	$	—	$	22,220,261	$	22,358,860
Health Care Equipment & Supplies		—		—		1,846,848		1,846,848
Pharmaceuticals		—		—		7,509,088		7,509,088
Convertible Notes
Biotechnology		—		—		885,140		885,140
Health Care Equipment & Supplies		—		—		1,184,267		1,184,267
Common Stocks and Warrants
Biotechnology		592,902,731		—		89,032		592,991,763
Drug Discovery Technologies		317,151		—		—		317,151
Health Care Equipment & Supplies		30,446,528		—		787,017		31,233,545
Health Care Providers & Services		29,043,756		—		735,555		29,779,311
Health Care Technology		530,247		—		—		530,247
Healthcare Services		2,001,754		—		—		2,001,754
Life Sciences Tools & Services		56,153,536		—		—		56,153,536
Medical Devices and Diagnostics		15,164,934		—		—		15,164,934
Pharmaceuticals		134,049,356		—		—		134,049,356
Exchange Traded Fund		6,686,288		—		—		6,686,288

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2019

(continued)

Assets at Value	Level 1		Level 2		Level 3		Total
Short-term Investment	$	—	$	38,139,000	$	—	$	38,139,000
Milestone Interests
Health Care Equipment & Supplies		—		—		4,593,349		4,593,349
Pharmaceuticals		—		—		8,827,333		8,827,333
Other Assets		—		—		1,189,264		1,189,264
Total	$	867,434,880	$	38,139,000	$	49,867,154	$	955,441,034
Other Financial Instruments
Assets
Option Contracts Purchased	$	39,325	$	—	$	—	$	39,325
Total	$	39,325	$	—	$	—	$	39,325

The following is a reconciliation of Level 3 assets for which significant unobservable inputs were used to determine fair value.

Level 3 Assets	Balance as of September 30, 2018		Net Realized gain (loss) and change in unrealized appreciation (depreciation)			Cost of purchases and conversions		Proceeds from sales and conversions			Net transfers in (out of) Level 3		Balance as of March 31, 2019
Convertible Preferred and Warrants
Biotechnology	$	17,110,039	($	212,636	)	$	9,808,006	($	4,485,148	)	$	0	$	22,220,261
Health Care Equipment & Supplies		1,846,848		0			0		0			0		1,846,848
Life Sciences Tools & Services		5,041,602		2,483,253			0		(7,524,855	)		0		0
Pharmaceuticals		5,599,998		0			1,909,090		0			0		7,509,088
Convertible Notes
Biotechnology		814,796		297			884,843		(814,796	)		0		885,140
Health Care Equipment & Supplies		998,417		0			185,850		0			0		1,184,267
Common Stocks and Warrants
Biotechnology		219,979		(130,947	)		0		0			0		89,032
Health Care Equipment & Supplies		677,075		109,942			0		0			0		787,017
Health Care Providers & Services		602,222		133,333			0		0			0		735,555
Milestone Interests
Health Care Equipment & Supplies		4,538,871		53,224			1,254		0			0		4,593,349
Pharmaceuticals		7,912,735		914,598			0		0			0		8,827,333
Other Assets		1,150,714		0			130,743		(92,193	)		0		1,189,264
	$	46,513,296	$	3,351,064		$	12,919,786	($	12,916,992	)	$	0	$	49,867,154
Net change in unrealized appreciation (depreciation) from investments still held as of March 31, 2019													($	1,462,011	)

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2019

(continued)

The following is a quantitative disclosure about significant unobservable inputs used in the determination of the fair value of Level 3 assets.

Fair Value at
March 31,
2019

Valuation Technique

Unobservable Input

Range
(Weighted Average)

Private Companies
and Other
Restricted Securities

$875,834

Income approach,
Black-Scholes

Discount for lack
of marketability

20%(20%)

17,629,327

Probability % weighted
expected return model

Discount rate
Price to sales multiple

24.24%-53.07% (39.60%)
3.65x-10.54x (6.45x)

13,048,190

Market approach,
recent transaction

(a)

N/A

3,703,957

Market Comparable

Discount for lack of
marketability
Earning ratio

15.00%-50.00% (21.95%)

4.60x-17.00x (7.06x)

14,609,846

Probability adjusted
value

Probability of events
Timing of events

15.00%-99.00% (45.59%)
0.25-25.00 (10.06) years

$49,867,154

(a) The valuation technique used as a basis to approximate fair value of these investments is based upon subsequent financing rounds. There is no quantitative information to provide as these methods of measure are investment specific.

(5) Private Companies and Other Restricted Securities

The Fund may invest in private companies and other restricted securities if these securities would currently comprise 40% or less of net assets. The value of these securities represented 5% of the Fund's net assets at March 31, 2019.

At March 31, 2019, the Fund had a commitment of $3,782,854 relating to additional investments in three private companies.

The following table details the acquisition date, cost, carrying value per unit, and value of the Fund's private companies and other restricted securities at March 31, 2019. The Fund on its own does not have the right to demand that such securities be registered.

Security (#)	Acquisition Date	Cost		Carrying Value per Unit		Value
Afferent Milestone Interest	07/27/16	$	377,701	$	783,096.00	$	783,096
Amphivena Therapeutics, Inc.
Series B Cvt. Pfd	07/17/17		4,902,852		15.00		4,900,001
Series C Cvt. Pfd	12/10/18		1,887,315		3.59		1,887,315
Atreca, Inc.
Series C1 Cvt. Pfd	09/05/18		1,649,999		2.33		1,649,999

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2019

(continued)

Security (#)	Acquisition Date	Cost		Carrying Value per Unit		Value
CardioKinetix, Inc.
Series C Cvt. Pfd	05/22/08	$	2,379,300	$	0.00	$	0
Series D Cvt. Pfd	12/10/10		785,862		0.00		0
Series E Cvt. Pfd	09/14/11		1,805,145		0.00		0
Series F Cvt. Pfd	12/04/14		2,368,365		0.00		0
Cvt. Promissory Note	06/20/17		74,505		0.00		0
Warrants (expiration 12/11/19)	12/10/09, 02/11/10		177		0.00		0
Warrants (expiration 06/03/20)	06/03/10, 09/01/10		177		0.00		0
Warrants (expiration 08/15/24)	08/15/14		204		0.00		0
Cercacor Laboratories, Inc. Common	03/31/98		0		4.92		786,802
Curasen Therapeutics, Inc.
Series A Cvt. Pfd	09/18/18		3,500,000		1.10		3,500,000
Decipher Biosciences, Inc.
Series II Cvt. Pfd	03/29/19		4,485,147		0.91		878,042
Series III Cvt. Pfd	03/29/19		1,014,421		2.17		2,090,360
Ethismos Research, Inc. Milestone Interest	10/31/17		0		0.00		0
Galera Therapeutics, Inc.
Series C Cvt. Pfd	08/30/18		2,310,060		2.21		2,310,000
IlluminOss Medical, Inc.
Series AA Cvt. Pfd	01/21/16		960,650		1.00		951,000
Junior Preferred	01/21/16		3,468,037		1.00		895,848
Cvt. Promissory Note	03/18/17		285,450		100.00		285,294
Cvt. Promissory Note	12/20/17		95,139		100.00		95,083
Cvt. Promissory Note	01/11/18		190,186		100.00		190,166
Cvt. Promissory Note	02/06/18		190,166		100.00		190,166
Cvt. Promissory Note	09/05/18		237,708		100.00		237,708
Cvt. Promissory Note	01/28/19		185,849		100.00		185,850
Warrants (expiration 01/11/28)	01/11/18		29		0.00		0
Warrants (expiration 01/29/29)	01/28/19		0		0.00		0
Warrants (expiration 11/20/27)	11/21/17		88		0.00		0
Warrants (expiration 02/06/28)	02/06/18		0		0.00		0
Warrants (expiration 03/31/27)	03/28/17		331		0.00		0
Warrants (expiration 09/06/27)	09/05/18		0		0.00		0
InnovaCare Health, Inc. Common	12/21/12†		965,291		3.31		735,555
Milestone Pharmaceuticals, Inc.
Series C Cvt. Pfd	07/17/17		2,102,920		1.37		2,099,998
Series D1 Cvt. Pfd	10/12/18		1,909,090		1.77		1,909,090
Neurovance Milestone Interest	03/20/17		4,917,881		2,683,575.00		2,683,575
Oculis SA,
Series B2 Cvt. Pfd	01/16/19		2,099,896		8.36		2,087,876
Rainier Therapeutics, Inc.
Series A Cvt. Pfd	01/19/16, 10/24/16		1,751,289		0.65		1,750,001
Series B Cvt. Pfd	03/03/17		1,166,744		0.75		1,166,667
Cvt. Promissory Note	01/30/19		442,570		100.00		442,570
Cvt. Promissory Note	03/28/19		442,570		100.00		442,570
TargeGen Milestone Interest	07/20/10		133,117		5,360,662.00		5,360,662

TEKLA HEALTHCARE INVESTORS

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2019

(continued)

Security (#)	Acquisition Date	Cost		Carrying Value per Unit		Value
Therachon Holding AG
Series B Cvt. Pfd	07/17/18	$	3,500,000	$	4.00	$	3,500,000
TherOx, Inc. Common	09/11/00, 07/08/05		3,582,705		0.02		215
Veniti Milestone Interest	08/16/18		4,010,784		4,593,349.00		4,593,349
		$	60,179,720			$	48,588,858

(#) See Schedule of Investments and corresponding footnotes for more information on each issuer.

† Interest received as part of a corporate action for a previously owned security.

TEKLA HEALTHCARE INVESTORS

INVESTMENT ADVISORY AGREEMENT APPROVAL

The Investment Advisory Agreement (the Advisory Agreement) between the Fund and the Adviser continues in effect so long as its continuance is approved at least annually by (i) the Trustees of the Fund and (ii) a majority of the Trustees of the Fund who are not interested persons (the Independent Trustees), by vote cast in person at a meeting called for the purpose of voting on such approval.

After considering the matter in a meeting held on March 21, 2019, the Board, and the Independent Trustees voting separately, determined that the terms of the Advisory Agreement are fair and reasonable and approved the continuance of the Advisory Agreement as being in the best interests of the Fund and its shareholders. In making its determination, the Board considered materials that were specifically prepared by the Adviser and by an independent data provider at the request of the Board and Fund counsel for purposes of the contract review process, including comparisons of (i) the Fund's performance both directly and on a risk adjusted basis to a benchmark, the NASDAQ Biotech Index^® (NBI), and to a peer group of other investment companies, (ii) the Fund's expenses and expense ratios to those of a peer group of other investment companies, and (iii) the Adviser's profitability with respect to its services for the Fund to the profitability of other investment advisers. The Trustees took into account that the Adviser provides investment management services only to Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund and does not derive any significant benefit from its relationship with the Fund other than receipt of advisory fees pursuant to the Advisory Agreement, market research and potential marketing exposure for the Adviser. The Board also received and reviewed information throughout the year about the portfolio performance, the investment strategy, the portfolio management team and the fees and expenses of the Fund. In their deliberations, the Independent Trustees had the opportunity to meet privately without representatives of the Adviser present and were represented throughout the process by counsel to the Independent Trustees and the Fund.

In approving the Advisory Agreement, the Board considered, among other things, the nature, extent, and quality of the services to be provided by the Adviser, the investment performance of the Fund and the Adviser, the costs of services provided and profits realized by the Adviser and its affiliates, and whether fee levels reflect any economies of scale for the benefit of Fund shareholders and the extent to which economies of scale would be realized as the Fund grows. The Board reviewed information about the foregoing factors and considered changes, if any, in such information since its previous approval. The Board also evaluated the financial strength of the Adviser and the capability of the personnel of the Adviser, specifically the strength and background of its investment analysts. Fund counsel provided the Board with the statutory and regulatory requirements for approval and disclosure of investment advisory agreements. The Board, including the Independent Trustees, evaluated all of the foregoing and, considering all factors together, determined in the exercise of its business judgment that the continuance of the Advisory Agreement is in the best interests of the Fund and its shareholders. The following provides more detail on certain factors considered by the Trustees and the Board's conclusions with respect to each such factor.

The nature, extent and quality of the services to be provided by the Adviser. On a regular basis the Board considers the roles and responsibilities of the Adviser as a whole, along with specific portfolio management, support and trading functions the Adviser provides to the Fund. The Trustees considered the nature, extent and quality of the services provided by the Adviser to the Fund. The Trustees continue to be satisfied with the quality and value of the investment advisory services provided to the Fund by the Adviser, and, in particular, the management style and discipline followed by the Adviser and the quality of the Adviser's research, trading, portfolio management, compliance and administrative personnel. The Trustees also took into

TEKLA HEALTHCARE INVESTORS

INVESTMENT ADVISORY AGREEMENT APPROVAL

(continued)

account the Adviser's significant investment in its business through the addition of portfolio management and administrative staff in recent years and the Adviser's commitment to continue to build out its infrastructure as future circumstances require.

The investment performance of the Fund and the Adviser. On a regular basis the Board reviews performance information of the Fund and discusses the Fund's investment strategy with the Adviser. The Trustees reviewed performance information for the Fund and in particular, performance information for the past one-, three-, five- and ten-year periods ending December 31, 2018, along with comparisons of the Fund's performance to its benchmark, the NBI. The Trustees also compared performance to a peer group of funds and reviewed information relating to the performance of the Fund's venture capital portfolio. The Trustees noted that the performance information reviewed reflects a view of the Fund's performance only as of a certain date, and that the results might be significantly different if a different date was selected to generate the performance information. Additionally, the Trustees recognized that longer periods of performance for the Fund may be adversely and disproportionately affected by significant underperformance in one more recent period, and that such underperformance may be caused by a small number of investment decisions or positions.

Unlike many other broader-based healthcare indices, the NBI contains high levels of biotechnology-based companies. Over time, this index has demonstrated higher returns, but has also demonstrated higher price volatility than the broad S&P 500^® Index. The Adviser seeks to operate the Fund at a biotechnology exposure level that is higher than many other indices and Funds but at a level that is below that of the NBI. The Adviser also seeks to operate the Fund at lower volatility than that of the NBI. In the current reporting period, the Adviser sought to do so by limiting exposure to biotechnology relative to the NBI and also by maintaining a higher exposure to large biotechnology companies (which typically exhibit relatively lower volatility) than is present in the NBI and lower exposure to small and mid-capitalization biotechnology companies than is present in the NBI.

The Trustees noted that in calendar year 2018, the Fund outperformed the return of the NBI on a direct comparison basis and also exhibited a lower volatility than that of the NBI. Over longer-term evaluation periods (three-year, five-year and ten-year periods), the Trustees noted that the Fund had operated at a lower volatility than the NBI, but underperformed (on a net asset value basis) the NBI on a direct comparison basis. The Trustees noted that the Fund underperformed the peer group average on a direct comparison basis both for calendar year 2018 and over longer-term evaluation periods, but produced returns comparable to the returns of those funds the Adviser believes are most similar to HQH (i.e., high biotech allocation funds) where measured.

In considering the Fund's relative performance, the Trustees noted that, although an independent service provider had been engaged to help identify the appropriate benchmark and peer group for the Fund, the Fund's unique strategy presents challenges when comparing the Fund's performance to a single benchmark or peer group as no single benchmark or fund within the peer group utilizes exactly the same investment strategy. In particular, the Trustees observed that the Fund's strategy has historically included a lower allocation to biotechnology compared to the NBI and a higher biotechnology allocation compared to many other healthcare indices and to many of the peer group funds. The Trustees noted, as a result, that all other things being equal, in periods when biotechnology performs relatively well, the Fund might be expected to underperform the NBI (and/or the peer group) and vice versa. Additionally, the Trustees noted that unlike the NBI and most of the peer group, the Fund often maintains a meaningful allocation to venture and restricted securities. In light

TEKLA HEALTHCARE INVESTORS

INVESTMENT ADVISORY AGREEMENT APPROVAL

(continued)

of these differences, the Trustees recognized the more limited usefulness of these performance comparisons for the Fund.

The Trustees concluded they continue to be satisfied with the investment performance of the Fund and the Adviser.

The costs of services to be provided and profits to be realized by the Adviser from its relationship with the Fund. The Trustees considered the various services provided by the Adviser to the Fund and reviewed comparative information regarding the expenses and expense ratios of the Fund and a peer group of other investment companies. The Trustees noted that the Adviser's fees are within the range of fees presented in the comparative information and noted that a portion of the Fund's investment portfolio is invested in venture and restricted securities, a portfolio management service that can warrant higher management fees than those charged by the Adviser to the Fund. The Trustees also considered financial information provided by the Adviser, including financial statements of the Adviser and a comparison of the Adviser's profitability with respect to its services for the Fund to the profitability of other investment advisers.

The Trustees noted that the fees charged by the Adviser are within a reasonable range of fees as compared to fees charged by other investment advisers, and the services provided by the Adviser and the amounts paid under the Advisory Agreement are at least comparable to the services rendered and fees charged by others for similar services to warrant a finding that fees to be paid by the Fund are fair. Based on the information provided to and evaluated by the Trustees, the Trustees concluded that the fees charged by the Adviser are fair and reasonable in light of the quality and nature of the services provided by the Adviser and that the profitability of the Adviser's relationship with the Fund has not been excessive.

Whether fee levels reflect economies of scale and the extent to which economies of scale would be realized as the Fund grows. The Trustees considered the advisory fee schedule in the Advisory Agreement and noted that it provides for breakpoints that would reduce the effective fee to the extent the Fund's net assets should increase, allowing the Fund to share in the benefits of any economies of scale that would inure to the Adviser as the Fund's assets increase. Given the closed-end structure of the Fund, its current asset size, and the fact that any economies of scale are modest at current Fund asset levels, the Trustees determined that the Fund's advisory fee schedule is satisfactory and fair.

TEKLA HEALTHCARE INVESTORS

PRIVACY NOTICE: If you are a registered shareholder of the Fund, the Fund and Tekla Capital Management LLC, the Fund's investment adviser, may receive nonpublic personal information about you from the information collected by the transfer agent from your transactions in Fund shares. Any nonpublic personal information is not disclosed to third parties, except as permitted or required by law. In connection with servicing your account and effecting transactions, the information received may be shared with the investment adviser and non-affiliates, including transfer agents, custodians or other service companies. Access to your nonpublic personal information is restricted to employees who need to know that information to provide products or services to you. To maintain the security of your nonpublic personal information, physical, electronic, and procedural safeguards are in place that comply with federal standards. The policies and practices described above apply to both current and former shareholders.

If your Fund shares are held in "street name" at a bank or brokerage, we do not have access to your personal information and you should refer to your bank's or broker's privacy policies for a statement of the treatment of your personal information.

FOR MORE INFORMATION: A description of the Fund's proxy voting policies and procedures and information on how the Fund voted proxies relating to portfolio securities during the most recent 12-month period ended June 30 is available (i) without charge, upon request by calling 1-800-451-2597; (ii) by writing to Tekla Capital Management LLC at 100 Federal Street, 19th Floor, Boston, MA 02110; (iii) on the Fund's website at www.teklacap.com; and (iv) on the SEC's website at http://www.sec.gov.

The Fund's complete Schedule of Investments for the first and third quarters of its fiscal year will be filed quarterly with the SEC on Form N-PORT. This Schedule of Investments will also be available on the Fund's website at www.teklacap.com, or the SEC's website at http://www.sec.gov.

You can find information regarding the Fund at the Fund's website, www.teklacap.com. The Fund regularly posts information to its website, including information regarding daily share pricing and distributions and press releases, and maintains links to the Fund's SEC filings. The Fund currently publishes and distributes quarterly fact cards, including performance, portfolio and sector information for each fiscal quarter. These fact cards will be available on the Fund's website and by request from the Fund's marketing and investor support services agent, Destra Capital Advisors, at 1-877-855-3434.

DISTRIBUTION POLICY: The Fund has a managed distribution policy as described in the Notes to Financial Statements. For more information contact your financial adviser.

SHARE REPURCHASE PROGRAM: In March 2019, the Trustees reauthorized the share repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares for a one year period beginning July 14, 2020.

PORTFOLIO MANAGEMENT: Daniel R. Omstead, PhD, Jason C. Akus, MD/MBA, Timothy Gasperoni, MBA, PhD, Christian M. Richard, MBA, MS, Henry Skinner, PhD, Ashton L. Wilson, Christopher Abbott, Robert Benson, CFA, CAIA, Richard Goss, Alan Kwan, MBA, PhD and Loretta Tsa, PhD are members of a team that analyzes investments on behalf of the Fund. Dr. Omstead exercises ultimate decision making authority with respect to investments.

HOUSEHOLDING: A number of banks, brokers and financial advisers have instituted "householding". Under this practice, which has been approved by the SEC, only one copy of shareholder documents may be delivered to multiple shareholders who share the same address and satisfy other conditions. Householding is intended to reduce expenses and eliminate duplicate mailings of shareholder documents. If you do not want the mailing of your shareholder documents to be combined with those of other members of your household, please contact your bank, broker or financial adviser.

TEKLA HEALTHCARE INVESTORS

New York Stock Exchange Symbol: HQH
NAV Symbol: XHQHX

100 Federal Street, 19th Floor
Boston, Massachusetts 02110
(617) 772-8500
www.teklacap.com

Officers

Daniel R. Omstead, PhD, President
Laura Woodward, CPA, Chief Compliance Officer,
Secretary and Treasurer

Trustees

Rakesh K. Jain, PhD
Thomas M. Kent, CPA
Elizabeth G. Nabel, MD
Daniel R. Omstead, PhD
Oleg M. Pohotsky, MBA, JD
William S. Reardon, MBA
Lucinda H. Stebbins, MBA, CPA

Investment Adviser

Tekla Capital Management LLC

Administrator & Custodian

State Street Bank and Trust Company

Transfer Agent

Computershare, Inc.

Legal Counsel

Dechert LLP

Shareholders with questions regarding share transfers may call

1-800-426-5523

Daily net asset value may be obtained from
our website (www.teklacap.com) or by calling

617-772-8500

Item 2. CODE OF ETHICS.

Not applicable to this semi-annual filing.

ITEM 3. AUDIT COMMITTEE FINANCIAL EXPERT.

Not applicable to this semi-annual filing.

ITEM 4. PRINCIPAL ACCOUNTANT FEES AND SERVICES.

Not applicable to this semi-annual filing.

ITEM 5. AUDIT COMMITTEE OF LISTED REGISTRANTS.

Not applicable to this semi-annual filing.

ITEM 6. INVESTMENTS.

The Registrant’s Schedule of Investments is included as part of the Report to Shareholders filed under Item 1 of this form.

ITEM 7. DISCLOSURE OF PROXY VOTING POLICIES AND PROCEDURES FOR CLOSED-END MANAGEMENT INVESTMENT COMPANIES.

Not applicable to this semi-annual filing.

ITEM 8. PORTFOLIO MANAGERS OF CLOSED-END MANAGEMENT INVESTMENT COMPANIES

Not applicable to this semi-annual filing.

ITEM 9. PURCHASES OF EQUITY SECURITIES BY CLOSED-END MANAGEMENT INVESTMENT COMPANY AND AFFILIATED PURCHASERS.

Period	(a) Total No. of Shares Purchased (1)		(b) Average Price Paid per Share	(c) Total No. of Shares Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum No. of Shares that May Yet Be Purchased Under the Plans or Programs
Month #1 (Oct. 1, 2018—Oct. 31, 2018)	335,801	(2)	20.94	326,419	4,693,020
Month #2 (Nov. 1, 2018— Nov. 30, 2018)	44,735		21.26	44,735	4,648,285
Month #3 (Dec. 1, 2018 — Dec. 31, 2018)	358,408	(2)	17.54	352,108	4,296,177
Month #4 (Jan. 1, 2019 — Jan. 31, 2019)	87,484		19.22	87,484	4,208,693
Month #5 (Feb. 1, 2019— Feb. 28, 2019)	—		—	—	4,208,693
Month #6 (Mar. 1, 2019 — Mar. 31, 2019)	—		—	—	4,208,693
Total	826,428		19.22	810,746

(1) On June 30, 2011, the share repurchase program was announced, which has been subsequently reviewed and approved by the Board of Trustees. On March 22, 2018 the share repurchase program was renewed, allowing the Registrant to repurchase up to 12% of its outstanding shares for a one year period ending July 14, 2019. On March 21, 2019, the Trustees approved the renewal of the repurchase program to allow the Registrant to repurchase up to 12% of its outstanding shares in the open market for a one year period ending July 14, 2020.

(2) 9,382 shares were purchased in Month #1 and 6,300 shares were purchased in Month #3 by Daniel R. Omstead in the open market. Dr. Omstead is a director of the Registrant and a controlling person of the Registrant's investment adviser. Accordingly, Dr. Omstead may be deemed an “affiliated purchaser” of the Registrant's shares as such term is defined by Rule 10b-18(a)(3) under the Exchange Act of 1934.

ITEM 10. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

There have been no material changes to the procedures by which the shareholders may recommend nominees to the Registrant’s Board of Trustees, where those changes were implemented after the Registrant last provided disclosure in response to the requirements of Item 7(d)(2)(ii)(G) of Schedule 14A, or this Item.

ITEM 11. CONTROLS AND PROCEDURES.

(a) In the opinion of the principal executive officer and principal financial officer, based on their evaluation which took place within 90 days of this filing, the Registrant’s disclosure controls and procedures are adequately designed and are operating effectively to ensure (i) that material information relating to the Registrant, including its consolidated subsidiaries, is made known to them by others within those entities, particularly during the period in which this report is being prepared; and (ii) that information required to be disclosed by the registrant on Form N-CSR is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission’s rules and forms.

(b) There were no changes in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal half-year that have materially affected or that are reasonably likely to materially affect the Registrant’s internal control.

ITEM 12. EXHIBITS

(a)(1) Code of Ethics - Not applicable to this semi-annual filing.

(a)(2) Separate certifications of the Principal Executive and Financial Officers as required by Rule 30a-2(a) under the 1940Act and Section 302 of the Sarbanes-Oxley Act of 2002 are attached hereto (Exhibit 1 and 2).

(a)(3) Notices to Fund’s shareholders in accordance with Investment Company Act Section 19(a) and Rule 19a-1 (Exhibit 3).

(b) Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 are attached hereto (Exhibit 4).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant)	TEKLA HEALTHCARE INVESTORS

By (Signature and Title)*	/s/ Daniel R. Omstead
	Daniel R. Omstead, President

Date:

6/5/19

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By (Signature and Title)*	/s/ Laura Woodward
	Laura Woodward, Treasurer

Date:

6/5/19

* Print the name and title of each signing officer under his or her signature.

EX-99.CERT 2 a19-7194_1ex99dcert.htm EX-99.CERT

EXHIBIT 99.CERT

EXHIBIT 1: CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Daniel R. Omstead, certify that:

1. I have reviewed this report on Form N-CSR of TEKLA HEALTHCARE INVESTORS;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the Registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	6/5/19	/s/ Daniel R. Omstead
		Name:	Daniel R. Omstead
		Title:	President

EXHIBIT 2: CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, Laura Woodward, certify that:

1. I have reviewed this report on Form N-CSR of TEKLA HEALTHCARE INVESTORS;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	6/5/19	/s/ Laura Woodward
		Name:	Laura Woodward
		Title:	Treasurer

EX-99.SECTION 19(A) 3 a19-7194_1ex99dsection19a.htm EX-99.SECTION 19(A)

Exhibit 99.Section 19(a)

EXHIBIT 3: NOTICES TO FUND’S SHAREHOLDERS IN ACCORDANCE WITH INVESTMENT COMPANY ACT

TEKLA HEALTHCARE INVESTORS

Notification of Sources of Distribution

Distribution Paid Date: December 31, 2018

Distribution Amount Per Common Share: $0.51

The following table sets forth the estimated amounts of the current distribution, paid December 31, 2018, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains, return of capital or other capital source. The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income’. All amounts are expressed per common share.

	Current Distribution		Percentage Breakdown of Current Distribution		Total Cumulative Distributions for the Fiscal Year to Date(1)		Percentage Breakdown of the Total Cumulative Distributions for the Fiscal Year to Date(1)
Net Investment Income	$	0.0000	0	%	$	0.0000	0	%
Net Realized ST Cap Gains	$	0.1671	33	%	$	0.1671	33	%
Net Realized LT Cap Gains	$	0.0000	0	%	$	0.0000	0	%
Return of Capital or Other Capital Source	$	0.3429	67	%	$	0.3429	67	%
TOTAL (per common share):	$	0.5100	100	%	$	0.5100	100	%

The table below includes information relating to the Fund’s performance based on its NAV for certain periods.

Average annual total return at NAV for the period from October 31, 2013 through October 31, 2018	7.34	%
Annualized current distribution rate expressed as a percentage of NAV as of October 31, 2018	9.03	%
Cumulative total return at NAV for the fiscal year, through October 31, 2018(2)	-11.83	%
Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of October 31, 2018(1)	2.26	%

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.

The composition of this and subsequent distribution may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized losses on sale of securities is $78,166,474, of which $94,064,713 represents net unrealized appreciation of portfolio securities.

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

(1)The Fund’s current fiscal year began on October 1, 2018.

(2)Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2018 through October 31, 2018.

Tekla Healthcare Investors

CUSIP: 87911J103
www.teklacap.com

Tekla Capital Management LLC
100 Federal Street, 19th Floor
Boston, Massachusetts 02110

617-772-8500

Fax: 617-772-8577

02YOAC 002CSN9913

TEKLA HEALTHCARE INVESTORS

Notification of Sources of Distribution

Distribution Paid Date: March 29, 2019

Distribution Amount Per Common Share: $0.41

The following table sets forth the estimated amounts of the current distribution, paid March 29, 2019, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains, return of capital or other capital source. The Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all the money that you invested in the Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income’. All amounts are expressed per common share.

	Current Distribution		Percentage Breakdown of Current Distribution		Total Cumulative Distributions for the Fiscal Year to Date(1)		Percentage Breakdown of the Total Cumulative Distributions for the Fiscal Year to Date(1)
Net Investment Income	$	0.0000	0	%	$	0.0000	0	%
Net Realized ST Cap Gains	$	0.0000	0	%	$	0.1671	18	%
Net Realized LT Cap Gains	$	0.0000	0	%	$	0.0000	0	%
Return of Capital or Other Capital Source	$	0.4100	100	%	$	0.7529	82	%
TOTAL (per common share):	$	0.4100	100	%	$	0.9200	100	%

The table below includes information relating to the Fund’s performance based on its NAV for certain periods.

Average annual total return at NAV for the period from January 31, 2014 through January 31, 2019	5.21	%
Annualized current distribution rate expressed as a percentage of NAV as of January 31, 2019	7.15	%
Cumulative total return at NAV for the fiscal year, through January 31, 2019(2)	-7.82	%
Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of January 31, 2019(1)	4.01	%

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.

The composition of this and subsequent distribution may vary from month to month because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized losses on sale of securities is $206,892,449, of which $217,458,636 represents net unrealized appreciation of portfolio securities.

(1)The Fund’s current fiscal year began on October 1, 2018.

Tekla Healthcare Investors

CUSIP: 87911J103
www.teklacap.com

Tekla Capital Management LLC
100 Federal Street, 19th Floor
Boston, Massachusetts 02110

617-772-8500

Fax: 617-772-8577

031FEB 002CSN9CDE

EX-99.906CERT 4 a19-7194_1ex99d906cert.htm EX-99.906CERT

Exhibit 99.906CERT

EXHIBIT 4: CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of TEKLA HEALTHCARE INVESTORS, do hereby certify, to such officer’s knowledge, that the report on Form N-CSR of TEKLA HEALTHCARE INVESTORS for the period ended March 31, 2019 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as applicable, and information contained in the Form N-CSR fairly presents, in all material respects, the financial condition and results of operations of TEKLA HEALTHCARE INVESTORS for the stated period.

Dated:	6/5/19

	/s/ Daniel R. Omstead		/s/ Laura Woodward
	Name:	Daniel R. Omstead	Name:	Laura Woodward
	Title:	President	Title:	Treasurer

A signed original of this written statement required by Section 906 has been provided to TEKLA HEALTHCARE INVESTORS and will be retained by TEKLA HEALTHCARE INVESTORS and furnished to the SEC or its staff upon request. This statement accompanies this report on Form N-CSR pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

GRAPHIC 5 j1971942_qxp001.jpg GRAPHIC begin 644 j1971942_qxp001.jpg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j1971942_qxp002.jpg GRAPHIC begin 644 j1971942_qxp002.jpg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end GRAPHIC 8 j1971942_qxp004.jpg GRAPHIC begin 644 j1971942_qxp004.jpg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end GRAPHIC 9 j1971942_qxp005.jpg GRAPHIC begin 644 j1971942_qxp005.jpg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j1971942_qxp006.jpg GRAPHIC begin 644 j1971942_qxp006.jpg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end GRAPHIC 11 j1971942_qxp007.jpg GRAPHIC begin 644 j1971942_qxp007.jpg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end